Most Read Articles
Christina Lau, 5 days ago
Progress in the treatment of rare cancers is named Advance of the Year by the American Society of Clinical Oncology (ASCO).
Jackey Suen, 08 Jul 2016

Scientists have refined anti-CD19 chimeric antigen receptor (CAR) T cell therapy, an investigational treatment for advanced non-Hodgkin’s lymphoma, with initial results showing significantly higher response and survival rates than the standard repertoire.

Podcast: CGP in NSCLC with Dr Alexander Drilon

07 Jul 2017
Podcast: CGP in NSCLC with Dr Alexander Drilon
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Christina Lau, 5 days ago
Progress in the treatment of rare cancers is named Advance of the Year by the American Society of Clinical Oncology (ASCO).
Jackey Suen, 08 Jul 2016

Scientists have refined anti-CD19 chimeric antigen receptor (CAR) T cell therapy, an investigational treatment for advanced non-Hodgkin’s lymphoma, with initial results showing significantly higher response and survival rates than the standard repertoire.